Pfizer says South African variant could significantly reduce vaccine protection | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Sunday
June 15, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SUNDAY, JUNE 15, 2025
Pfizer says South African variant could significantly reduce vaccine protection

Coronavirus chronicle

Reuters
18 February, 2021, 09:55 am
Last modified: 18 February, 2021, 10:01 am

Related News

  • Covid-19: One death, 26 new cases reported in 24hrs
  • 7 new Covid-19 cases reported in 24hrs
  • Covid hospitals in Chattogram face ICU, testing kit crisis amid rising infections
  • DGHS issues 11-point directive to prevent spread of Covid-19 in Bangladesh
  • Tourist surge raises fresh Covid-19 concerns in Rangamati

Pfizer says South African variant could significantly reduce vaccine protection

Because there is no established benchmark yet to determine what level of antibodies are needed to protect against the virus, it is unclear whether that two-thirds reduction will render the vaccine ineffective against the variant spreading around the world

Reuters
18 February, 2021, 09:55 am
Last modified: 18 February, 2021, 10:01 am
Photo: Collected.
Photo: Collected.

A laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from the Pfizer Inc/BioNTech SE vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday.

The study found the vaccine was still able to neutralize the virus and there is not yet evidence from trials in people that the variant reduces vaccine protection, the companies said.

Still, they are making investments and talking to regulators about developing an updated version of their mRNA vaccine or a booster shot, if needed.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

For the study, scientists from the companies and the University of Texas Medical Branch (UTMB) developed an engineered virus that contained the same mutations carried on the spike portion of the highly contagious coronavirus variant first discovered in South Africa, known as B.1.351. The spike, used by the virus to enter human cells, is the primary target of many Covid-19 vaccines.

Researchers tested the engineered virus against blood taken from people who had been given the vaccine, and found a two- thirds reduction in the level of neutralizing antibodies compared with its effect on the most common version of the virus prevalent in US trials.

Their findings were published in the New England Journal of Medicine (NEJM).

Because there is no established benchmark yet to determine what level of antibodies are needed to protect against the virus, it is unclear whether that two-thirds reduction will render the vaccine ineffective against the variant spreading around the world.

However, UTMB professor and study co-author Pei-Yong Shi said he believes the Pfizer vaccine will likely be protective against the variant.

"We don't know what the minimum neutralizing number is. We don't have that cutoff line," he said, adding that he suspects the immune response observed is likely to be significantly above where it needs to be to provide protection.

That is because in clinical trials, both the Pfizer/BioNTech vaccine and a similar shot from Moderna Inc conferred some protection after a single dose with an antibody response lower than the reduced levels caused by the South African variant in the laboratory study.

Even if the concerning variant significantly reduces effectiveness, the vaccine should still help protect against severe disease and death, he noted. Health experts have said that is the most important factor in keeping stretched healthcare systems from becoming overwhelmed.

More work is needed to understand whether the vaccine works against the South African variant, Shi said, including clinical trials and the development of correlates of protection - the benchmarks to determine what antibody levels are protective.

Pfizer and BioNTech said they were doing similar lab work to understand whether their vaccine is effective against another variant first found in Brazil.

Moderna published a correspondence in NEJM on Wednesday with similar data previously disclosed elsewhere that showed a sixfold drop antibody levels versus the South African variant.

Moderna also said the actual efficacy of its vaccine against the South African variant is yet to be determined. The company has previously said it believes the vaccine will work against the variant.

Top News

Pfizer coronavirus vaccine / Pfizer Covid-19 Vaccine / Pfizer vaccine / Pfizer-19 Vaccine / Pfizer-BioNTech vaccine / Pfizer-BioNTech coronavirus vaccine / Pfizer Inc / Coronavirus Vaccine / Covid-19 Vaccine / Covid / Covid -19 / Covid 19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Banks' classified loans soar by Tk74,570cr in 3 months, hit Tk4.2 lakh crore
    Banks' classified loans soar by Tk74,570cr in 3 months, hit Tk4.2 lakh crore
  • A missile is launched during an air defence drill in an undisclosed location in Iran, in this handout image obtained on January 12, 2025. Photo: Iranian Army/WANA (West Asia News Agency)/Handout via REUTERS
    Investors on edge over Israel-Iran conflict, oil price volatility
  • News of The Day, 15 JUNE 2025
    News of The Day, 15 JUNE 2025

MOST VIEWED

  • Vehicles were seen stuck on the Dhaka-Tangail-Jamuna Bridge highway due to a traffic jam stretching 15 kilometres on 14 June 2025. Photo: TBS
    15km traffic jam on Dhaka-Tangail-Jamuna Bridge highway as post-Eid rush continues
  • Tour operator Borsha Islam. Photo: Collected
    ‘Tour Expert’ admin Borsha Islam arrested over Bandarban tourist deaths
  • Infographic: TBS
    Chattogram Port proposes 70%-100% tariff hike
  • Fighter jet. Photo: AFP
    3 F-35 fighter jets downed, two Israeli pilots in custody, claims Iranian media
  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Merger of 5 Islamic banks at final stage: BB governor
  • Infograph: TBS
    Why 10 economic zones, including BGMEA's garment park, were cancelled

Related News

  • Covid-19: One death, 26 new cases reported in 24hrs
  • 7 new Covid-19 cases reported in 24hrs
  • Covid hospitals in Chattogram face ICU, testing kit crisis amid rising infections
  • DGHS issues 11-point directive to prevent spread of Covid-19 in Bangladesh
  • Tourist surge raises fresh Covid-19 concerns in Rangamati

Features

Renowned authors Imdadul Haque Milon, Mohit Kamal, and poet–children’s writer Rashed Rouf seen at Current Book Centre, alongside the store's proprietor, Shahin. Photo: Collected

From ‘Screen and Culture’ to ‘Current Book House’: Chattogram’s oldest surviving bookstore

3h | Panorama
Photos: Collected

Kurtis that make a great office wear

2d | Mode
Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

4d | Panorama
Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

5d | Features

More Videos from TBS

New Weapons, Old Rivalry: Iran Fires Missiles at Israel

New Weapons, Old Rivalry: Iran Fires Missiles at Israel

1h | TBS World
5 Islamic banks to merge into one, no one will lose their jobs: BB governor

5 Islamic banks to merge into one, no one will lose their jobs: BB governor

2h | TBS Today
How the world is reacting to Israel attacks on Iran?

How the world is reacting to Israel attacks on Iran?

2h | TBS World
Chattogram Port proposes 70%-100% tariff hike

Chattogram Port proposes 70%-100% tariff hike

3h | TBS Insight
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net